RPL19

Across TCGA pan-cancer cohorts, RPL19 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RPL19 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RPL19 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL19 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and GBM are the cancer types where RPL19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.709	1.000	.001	23	view →
LUAD	DFS	Median	All	0.754	0.443	.008	16	view →
GBM	DFS	Tertile	All	0.281	0.541	.011	15	view →
LSCC	OS	Tertile	II,III,IV	0.951	0.648	.019	10	view →
CCRCC	DFS	Median	All	0.704	1.000	.008	8	view →
UCEC	OS	Quartile	All	1.000	0.854	.028	4	view →
PDAC	DFS	Tertile	III,IV	0.779	0.352	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RPL19–HNSC (DFS)

Open the HNSC breakdown →